Introduction
Glycolysis is an ubiquitous metabolic pathway. In addition to its catabolic role, glycolysis also serves an anabolic function by providing C3 precursors for the synthesis of fatty acids, cholesterol and amino acids. It is therefore an amphibolic pathway. The difference in metabolic orientation is tissue-specific and depends on the hormonal and nutritional state. Therefore, it is not surprising that different and specific regulatory mechanisms exist to control glycolysis under these various conditions. Cancer cells are a special case in which glycolysis is abnormally high.
Qualitative and quantitative approaches have been developed to elucidate the control mechanisms of glycolysis. On the one hand, so-called 'rate-limiting' steps in the pathway have been identified by qualitative analysis. Reactions displaced far from equilibrium, particularly when catalysed by an allosterically regulated enzyme, have been assumed to qualify for control [1] . One such reaction is catalysed by phosphofructokinase (PFK-1). The experimental evidence supporting the key role of PFK-1 stems from the changes in the concentration of PFK-1 effectors observed when glycolysis is stimulated, e.g. following anoxia [2, 3] . However, this information remains qualitative and may lead to an oversimplified view. On the other hand, the quantitative analysis of control, developed by Kacser & Burns [4] and Heinrich & Rapoport [5] , allows the distribution of control among all steps in a pathway to be calculated. Such an approach has been applied to glycolysis in erythrocytes [6] and yeast [7] , and it indicates that control is mainly distributed between hexokinase and PFK-1.
The study of the mechanism of action of glucagon on liver gluconeogenesis led to the discovery of fructose 2,6-bisphosphate (Fru-2,6-P2) [8, 9] . This sugar phosphate is a potent stimulator of PFK-1 [10] [11] [12] and is also an inhibitor of fructose 1,6-bisphosphatase (FBPase-l) [13, 14] . Fru-2,6-P2 has been detected in all mammalian tissues studied so far, as well as in fungi and plants, but not in prokaryotes [15] .
Earlier reviews have dealt with the effect of Fru-2,6-P2 on its two main targets, PFK-1 and FBPase-1, together with the regulation of its synthesis and breakdown in relation to the control of glycolysis/gluconeogenesis in liver [15] [16] [17] [18] [19] [20] [21] [22] . Since Fru-2,6-P2 is present in all mammalian tissues, it is tempting to suppose that it plays the major role in the control of glycolysis. The purpose of this article is to specify the conditions under which Fru-2,6-P2 plays a role in the control of glycolysis, and to review recent studies dealing with Fru-2,6-P2 metabolism in mammalian tissues other than liver. Control of enzyme activity by Fru-2,6-P2
The two main targets of Fru-2,6-P2 are PFK-l and FBPase-1. Different isoenzyme forms of PFK-I exist, all of which display similar kinetic properties [23, 24] . ATP, one of the substrates of PFK-1, behaves as a negative allosteric effector inducing co-operativity for fructose 6-phosphate (Fru-6-P), the second substrate. This inhibition by ATP can be relieved by Fru-6-P acting as a positive effector. The most important positive effectors are AMP and Fru-2,6-P2, which act in synergism. All PFK-1 isoenzymes studied so far are sensitive to Fru-2,6-P2 [15] . In the presence of physiological concentrations of substrates and effectors, liver PFK-1 is almost completely inactive [25] unless micromolar concentrations ofFru-2,6-P2 (within the physiological range) relieve the inhibition by ATP and allow glycolysis to proceed [10] [11] [12] . Thus, in liver and perhaps in other tissues, Fru-2,6-P2 is a likely candidate to stimulate PFK-l when the anabolic role of glycolysis prevails. In contrast, when glycolysis is the only source of ATP as, e.g., during anoxia, adenine nucleotides and Pi probably play the main regulatory role.
Fructose 1,6-bisphosphate (Fru-1,6-P2), the product of the reaction catalysed by PFK-1, is yet another positive effector of this enzyme. Its concentration varies greatly in the cell and it binds to the same site as Fru-2,6-P2 [26] . While the affinity of PFK-1 for Fru-2,6-P2 is at least 100-fold greater than for Fru-1,6-P2 in liver, it is only 10-fold greater in muscle [10, 26, 27] . Therefore, when the concentration of Fru-1,6-P2 largely exceeds that of Fru-2,6-P2 as, e.g., in contracting muscle [28, 29] , the effect of Fru-1,6-P2 would prevail over that of Fru-2,6-P2.
An interesting property of muscle PFK-1 is that its activity and response to regulatory ligands are influenced by its concentration and protein-protein interaction [30, 31] . For example, binding of PFK-1 to membranes [32] or myofibrils [33] relieves inhibition by ATP, thereby stimulating enzyme activity. Therefore translocation of PFK-1 may be an important control mechanism in vivo. This translocation and the equilibrium between free and bound PFK-1, in turn, could be influenced by ligands and/or phosphorylation state of the enzyme [34] of the cyclic AMP-dependent protein kinase [35, 36] . Phosphorylation affects the kinetic properties of muscle PFK-1 so that phosphorylated PFK-1 becomes less active (the affinity for positive effectors decreases and inhibition by ATP increases) [35, [37] [38] [39] [40] . However, the changes for the liver enzyme are small and have not always been observed [41] . Muscle PFK-1 is also a substrate of the Ca2+-activated, phospholipid-dependent protein kinase (protein kinase C). Phosphorylation activates the enzyme by increasing the affinity for Fru-6-P [42] . Whether this effect is physiologically significant is questionable, since positive effectors such as Fru-2,6-P2
inhibit the phosphorylation in vitro [43] . Muscle PFK-1 has also been reported to be a substrate of the tyrosine kinase activity of the purified epidermal growth factor receptor [44] ; whether phosphorylation modifies the kinetic properties of PFK-1 and can occur in the intact cells is not known. The changes in activity of phosphorylated PFK-1 from adipose tissue are discussed below.
Fru-2,6-P2 is an inhibitor of FBPase-l [13, 14] . The inhibition by Fru-2,6-P2 is synergistic with that by AMP (except for muscle enzyme [45] ), and greater at low than at high substrate concentration. Fru-2,6-P2 changes the saturation curve for the substrate from a hyperbolic to a sigmoidal shape, suggesting an allosteric type of interaction. From kinetic and binding studies it appears that the action of Fru-2,6-P2 is complex and involves its binding to a site which might be different from the Fru-1,6-P2 site, although some overlapping between the two sites is not excluded (for a review see [15] 
inhibition of FBPase-l in vivo. In contrast, PFK-1 is completely inactive during gluconeogenesis [47] . These observations suggest that FBPase-1 is less inhibited in vivo than would be expected from measurements in vitro and that the concentration of free AMP and Fru-2,6-P2 are probably less than their total cytosolic concentration. In addition, FBPase-1 is less sensitive to the effect of Fru-2,6-P2 than PFK-1. Moreover, kinetic and binding studies have shown that the affinity of FBPase-1 for Fru-2,6-P2 is about 10-fold smaller than that of PFK-1 [10] [11] [12] [13] [14] 27, 48, 49] .
Liver FBPase-I from rat, but not from mouse, rabbit or pig, is a substrate of the cyclic AMP-dependent protein kinase [50] [51] [52] [53] [54] . Phosphorylation decreases the Km for Fru-1,6-P2 but does not affect the response to AMP and Fru-2,6-P2. The phosphorylation site is located in the C-terminal region of the rat enzyme. This site is not present in the other species, and the physiological relevance of this phosphorylation is obviously restricted.
Besides its effect on PFK-1 and FBPase-1, Fru-2,6-P2 has been reported to affect several other enzymes. It stimulates pyrophosphate: fructose 6-phosphate phosphotransferase, an enzyme present in plants [55] . Because of its. extreme sensitivity towards Fru-2,6-P2, this enzyme from potato tubers is used for the microassay of Vol. 245 Fru-2,6-P2 [56, 57] . Fru-2,6-P2 has been reported to affect the activity of UDPGlc phosphorylase [58] , trehalose phosphorylase [59] , 6-phosphogluconate dehydrogenase [60] and phosphoglucomutase [61] . These effects have not always been confirmed, and some require high nonphysiological concentrations of Fru-2,6-P2. An unusual situation exists in Trypanosoma brucei, in which Fru-2,6-P2 does not affect PFK-1 but stimulates pyruvate kinase activity [62] . Biosynthesis and degradation of Fru-2,6-P2
The steady state concentration of Fru-2,6-P2 depends on the balance between the activities of 6-phosphofructo-2-kinase (PFK-2), which synthesizes Fru-2,6-P2, and fructose-2,6-bisphosphatase (FBPase-2) which catalyses its breakdown. The properties of this system have been extensively studied in rat liver and are summarized below for comparison with those in other tissues (for a review see also [63] ).
PFK-2 catalyses the synthesis of Fru-2,6-P2 from Fru-6-P and MgATP. The enzyme is saturated by MgATP, stimulated by Pi and inhibited by citrate, phosphoenolpyruvate and sn-glycerol 3-phosphate at physiological concentrations. In the presence of 5 mM-Ps, the Km of PFK-2 for Fru-6-P is 50^M , a concentration also in the physiological range [15] .
The hydrolysis of Fru-2,6-P2 to Fru-6-P and Pi is catalysed by a specific phosphatase, FBPase-2, which is stimulated by Pi, sn-glycerol 3-phosphate and nucleoside triphosphates. The Km of this enzyme for Fru-2,6-P2 is less than 0.1 M, which is 100 times less than the total concentration of Fru-2,6-P2 in the livers of fed rats. Fru-6-P, one of the reaction products, inhibits the enzyme which an apparent Ki of about 20,uM [15] . Therefore, since both the Km of PFK-2 and the Ki of FBPase-2 for Fru-6-P are similar to the concentrations of Fru-6-P normally found in the liver, any change in Fru-6-P concentration should cause inverse changes in the two activities. A direct relation between the concentrations of Fru-6-P and Fru-2,6-P2 has indeed been found in the liver under certain conditions [64] .
The activities of PFK-2 and FBPase-2 copurify with a protein of Mr 110000, composed of two identical subunits of Mr 55000. Several lines of evidence suggest that this protein is a bifunctional enzyme with two distinct catalytic sites on the same polypeptide chain [65] [66] [67] [68] . The liver bifunctional PFK-2/FBPase-2 is a substrate of cyclic AMP-dependent protein kinase which inactivates PFK-2 and activates FBPase-2 (see below).
The PFK-2 reaction appears to involve the formation of a ternary complex, whereas the FBPase-2 reaction follows a ping-pong mechanism involving a phosphoryl enzyme (E-P) intermediate. Indeed incubation of the bifunctional enzyme with Fru-2,6-[2-32P]P2 leads to the phosphorylation of a histidine residue and the rate of enzyme phosphorylation is 100 times faster than the overall rate of hydrolysis [69] [70] [71] [72] .
Sulphydryl groups appear to be important for both PFK-2 and FBPase-2 activities [73] .
Evidence for the possible existence of isoenzymes of PFK-2/FBPase-2 was first obtained when the properties of purified bovine heart and rat liver enzymes were compared [74] . The study revealed that the two enzymes differ by their relative FBPase-2 content, kinetic properties, response to treatment by cyclic AMPdependent protein kinase and protein kinase C and labelling from Fru-2,6-[2-32P]P2 [7476] ( Table 1 ). In addition, antiserum raised against rat liver PFK-2 does not cross-react with the heart enzyme [76] . A striking difference between type H (heart) and type L (liver) PFK-2/FBPase-2 is the low heart FBPase-2 activity, which is 80 times smaller than the PFK-2 activity [75] . One report has even claimed that heart PFK-2 is devoid of any FBPase-2 activity [76] . This has not been confirmed [75] . The fact that heart FBPase-2 is not activated by cyclic AMP-dependent protein kinase suggests that the low heart FBPase-2 activity is not due to contamination by type L isoenzyme [63] . Thus, the heart bifunctional enzyme is more a kinase than a phosphatase. Heart FBPase-2 activity is too small (0.01 nmol/min per g of tissue) to account for the changes in Fru-2,6-P2 concentration observed in vivo. This suggests that either some hitherto unknown factor(s) could unmask the bisphosphatase activity in vivo, or that another FBPase-2 exists. Until now, however, all attempts to detect and purify another specific FBPase-2 have failed (M. H. Rider, A. M. Loiseau & L. Hue, unpublished results). On the other hand, it is not excluded that, Fru-2,6-P2 could act as a substrate for other reactions. Fru-2,6-P2 is indeed a potential donor of either Xa phosphoryl or an osyl group, but no such reactions have yet been described. By contrast with the type H, muscle PFK-2/FBPase-2 contains 5-10 times more phosphatase than kinase activity, and, in this respect, muscle PFK-2/FBPase-2 is more a phosphatase than a kinase and it resembles the phosphorylated form of liver PFK-2/FBPase-2 [63, 77] . The enzyme has been purified to homogeneity from pigeon muscle [77] . However, unlike the type L but like the type H, muscle PFK-2 is not inactivated by treatment with cyclic AMP-dependent protein kinase [63, 77] . Therefore, since muscle PFK-2/FBPase-2 differs from both the type L and H, the question is whether the muscle enzyme represents a third isoenzyme of PFK-2/FBPase-2. Immunological studies could help in answering this question. In spite of these different regulatory properties, the three enzymes have a similar molecular mass.
An interesting feature of rat skeletal muscle FBPase-2 activity is that its Ki (140 JaM) for Fru-6-P is more than 5 times greater than that of liver FBPase-2 [63] . This may explain why muscle contraction, which results in a rise in Fru-6-P, does not always lead to a corresponding rise in Fru-2,6-P2 [28, 29] . In all mammalian tissues studied so far, it has been possible to measure PFK-2 activity as well as the formation of E-P from Fru-2,6-[2-32P]P2, suggesting the existence of a FBPase-2 activity. The PFK-2 activity (about 2-5 nmol/min per g in all mammalian tissues) is several orders of magnitude smaller than the activity of hexokinase, PFK-1 and pyruvate kinase, and than the overall glycolytic rate. This implies that the PFK-2/ FBPase-2 dependent changes in Fru-2,6-P2 concentration are too slow to qualify for instantaneous control of glycolysis as it is required, e.g. during muscle contraction. On the other hand, since both the activity per g of tissue and the specific activity of PFK-2/FBPase-2 are much smaller than those of other glycolytic enzymes, the intracellular concentration ofPFK-2/FBPase-2 in liver is comparable with that of PFK-1 [78] . Control of PFK-2/FBPase-2 activity by phosphorylation
In liver, stimulation of gluconeogenesis by glucagon involves inhibition of glycolysis, which results not only from the inactivation of pyruvate kinase but also from the disappearance of Fru-2,6-P2 [19] . This glucagon effect on Fru-2,6-P2 probably results from the phosphorylation of PFK-2/FBPase-2. The liver bifunctional enzyme indeed belongs to the growing number of enzymes controlled by phosphorylation/dephosphorylation [65] . The cyclic AMP-dependent protein kinase catalyses the incorporation of 1 mol of phosphate/mol of 55 kDa subunit [79, 80] .
Partial proteolysis of the phosphorylated enzyme with thermolysin removes a single phosphorylated peptide which contains three adjacent arginine residues Nterminal to the phosphorylated serine [79] . This is more than the two basic residues required for site specificity, and may explain why liver PFK-2 is such a good substrate for cyclic AMP-dependent protein kinase.
The phosphorylation site of other liver glycolytic enzymes phosphorylated by the cyclic AMP-dependent protein kinase is likewise released by partial proteolysis on a low-Mr fragment. These enzymes include PFK-1 [37] , FBPase-1 [52] and pyruvate kinase [81] . Thus the location of phosphorylation sites at the extremities of the protein structure may be a general feature by which the effects of phosphorylation are transmitted. Table 2 . Relationship between Fru-2,6-P2 concentration and glycolytic flux in liver
The concentration of Fru-2,6-P2 in liver is between 0.1 and 20 nmol/g wet wt. depending on the conditions. Three metabolic states are listed. In the first, Fru-2,6-P2 is low, gluconeogenesis prevails and glycolysis is blocked. The last five conditions listed in the first group decrease Fru-2,6-P2 concentrations but do not necessarily inhibit lactate production and/or stimulate gluconeogenesis. In the second metabolic state, Fru-2,6-P2 is between 5 and 20 nmol/g, glycolysis prevails but gluconeogenesis is not stopped, therefore futile cycles occur. In the third state, Fru-2,6-P2 is low and glycolysis is maximally stimulated by anoxia. For details, see the text. Moreover, the phosphorylated FBPase-2 is more sensitive to stimulation by nucleoside triphosphates and glycerol phosphate, and less sensitive to inhibition by Fru-6-P [15, 83] .
Inactivation and phosphorylation of liver PFK-2 is inhibited by Fru-2,6-P2 [84] (half-maximal effect at 0.5 /LM [85] ). The physiological relevance of this observation is not clear since, in hepatocytes from fed rats, 10-20,M-Fru-2,6-P2 does not prevent glucagon from inactivating PFK-2 [86] . This suggests that other positive ligands could antagonize the effect of Fru-2,6-P2, and sn-glycerol 3-phosphate is a potential candidate. Indeed, Vol. 245 sn-glycerol 3-phosphate, which accumulates in hepatocytes treated with ethanol, favours PFK-2 inactivation and FBPase-2 activation in vitro, thereby offering an explanation for the effect of ethanol to decrease Fru-2,6-P2 concentration in hepatocytes [85] .
Incubation of intact hepatocytes with glucagon results in the phosphorylation of PFK-2/FBPase-2 [87] . However, phosphorylation of the bifunctional enzyme in intact hepatocytes has not been correlated with hormone concentration, cyclic AMP concentration and activities of PFK-2/FBPase-2. Therefore, the final criterion of Krebs & Beavo [88] to definitely establish control by phosphorylation/dephosphorylation has not been satisfied. According to Nimmo & Cohen's criteria [89] it also remains to be shown that the site phosphorylated in glucagon-treated hepatocytes is the same as that phosphorylated by cyclic AMP-dependent protein kinase in vitro.
Liver PFK-2 has been reported to be phosphorylated and inactivated by phosphorylase kinase [66] . This effect is probably not relevant to the situation in vivo, because hormones like vasopressin and a-adrenergic agents, which stimulate phosphorylase kinase by mobilizing Ca2+, do not cause phosphorylation of PFK-2 in hepatocytes [90] . Moreover, unlike glucagon, these agents increase the concentration of Fru-2,6-P2 in hepatocytes [64, 91] (see below).
Protein kinase C has been shown to phosphorylate heart, but not liver, PFK-2. Phosphorylation did not affect PFK-2/FBPase-2 activity [75] . It is not known whether PFK-2 isoenzymes from other tissues are also substrates for protein kinase C. This is particularly relevant to the stimulation of glycolysis and the activation of PFK-2 that are observed after treatment of fibroblasts with phorbol esters [92] , which are known activators of protein kinase C.
Reversal of phosphorylation is catalysed by phosphoprotein phosphatase(s) which, in the classification system of Cohen and co-workers [93] , correspond to type 2A and 2C phosphatase [94, 95] .
Regulation of PFK-2/FBPase-2 activity by cyclic AMP-dependent protein kinase has not been reported for tissues other than liver. Therefore, the latter appears as the exception rather than the rule. Interestingly, PFK-2 from yeast is a substrate of cyclic AMP-dependent protein kinase which, contrary to the case in liver, activates the enzyme [96] .
Relationship between glycolytic flux and Fru-2,6-P2 concentration in liver Three metabolic states of the liver can be considered (Table 2 ). In the first, gluconeogenesis occurs and glycolysis is stopped so that futile cycling of metabolites is avoided. This situation is typical of fasting, diabetes, and glucagon treatment [19, 47] . Under these conditions, the concentration of Fru-2,6-P2 is very low (below 1 ,UM). This can be explained by the inactivation of PFK-2 and activation of FBPase-2 resulting from phosphorylation of the enzyme by cyclic AMP-dependent protein kinase [86] . Other agents acting through cyclic AMP have the same effect. The fall in Fru-2,6-P2 concentration leads to inhibition of PFK-1 activity and, since glucagon also casues the inactivation of pyruvate kinase [97] , the glycolytic flux is effectively blocked by this dual lock [19, 47] . However, when glucagon is administered to fed animals, liver glycolysis is inhibited but not completely blocked, so that cycling between glucose and triose phosphate persists [8, 46, 47] . This is explained by the fact that glucagon stimulates glycogen breakdown, thereby producing a massive increase in hexose 6-phosphate concentration [98] which antagonizes the glucagoninduced inactivation of PFK-2 and activation of FBPase-2.
A decrease in Fru-2,6-P2 seems to be required for the glucagon stimulation of gluconeogenesis from substrates entering at the level of triose phosphates. By contrast, with substrates entering at the level of pyruvate, the inactivation of pyruvate kinase by glucagon appears to be the major regulatory component [99] . The latter conclusion is in agreement with the results of the quantitative analysis of control performed by Groen and co-workers [100] .
A fall in Fru-2,6-P2 concentration is also obtained in regenerating liver (L. Hue, unpublished work) or in hepatocytes incubated with adenosine [101] , ethanol [85] , fatty acids (L. Hue, L. Maisin & M. H. Rider, unpublished work), or relatively large concentration of gluconeogenic precursors such as lactate, pyruvate, alanine or fructose [99, 102] . The mechanisms responsible for the fall in Fru-2,6-P2 under these conditions may involve changes in the activities of PFK-2/FBPase-2 induced by variations in the concentration ofmetabolites. Phosphoenolpyruvate, citrate and mainly sn-glycerol 3-phosphate are important in this respect, since they are known to exert a dual inhibitory action on PFK-2. Indeed, they are not only inhibitors of PFK-2 activity but they also promote the cyclic AMP-dependent phosphorylation of PFK-2/FBPase-2 [77, 85] .
The second metabolic state corresponds to the anabolic fed state when glucose is abundant as, e.g., after a carbohydrate meal. Under this condition the liver takes up glucose, some being stored as glycogen, while the rest is transformed into lactate and fatty acids. Glucose by itself is able to control both the synthesis of glycogen and glycolysis; it is not known whether it can also monitor the synthesis de novo of fatty acids. The stimulation of glycolysis by glucose can be explained by the increase in Fru-2,6-P2 concentration [8, 64] . Glycogen metabolism is also glucose-sensitive, with phosphorylase acting as a glucose sensor [103, 104] . It appears that the glucose sensitivity of the liver for glycolysis is not the same as that for glycogen synthesis. In fasted animals, the activation of glycogen synthase requires less glucose than does the stimulation of glycolysis. The opposite situation is observed in livers of fed animals [78] . The physiological meaning of this observation is that in the fasted state, the glycogen stores are first replenished (from glucose or from gluconeogenic precursors), and it is only when an excess of glucose is given that gluconeogenesis is inhibited and lactate produced. This difference in sensitivity should be taken into consideration when discussing 'the glucose paradox' [105] , namely that after glucose administration to fasted rats, gluconeogenesis persists and liver glycogen is synthesized mainly from gluconeogenic precursors [106] [107] [108] [109] .
An increase in liver Fru-2,6-P2 is not only obtained after a glucose load in normal animals. It is also observed even during fasting in livers of genetically obese mice and rats [110] [111] [112] . This high glycolysis may contribute to obesity by keeping lipogenesis active even in the fasted state.
Studies with isolated hepatocytes from normal rats have shown that the relationship between Fru-2,6-P2 concentration and lactate release holds only at relatively high Fru-2,6-P2 concentration (above 5 nmol/g) [78] . This lack of correlation could result from the recycling of metabolites (PFK-1 and FBPase-1 both active and no net lactate production) which is actually observed [8] . It can also result from binding of Fru-2,6-P2 to proteins. From the maximal binding capacity of liver cytosolic proteins one can calculate that, at 5 ,UM, more than 90% of Fru-2,6-P2 is indeed sequestered to proteins [78] .
Therefore the metabolic significance of Fru-2,6-P2 is best expressed at relatively high concentrations when it allows the liver to switch from gluconeogenesis to glycolysis and vice versa.
An increase in Fru-2,6-P2 is also observed in isolated hepatocytes incubated with low' concentrations (below 5 mM of gluconeogenic precursors such as fructose, dihydroxyacetone, lactate or pyruvate [99] . Similarly, incubation of hepatocytes from fed rats with vasopressin or a-adrenergic agonists increase Fru-2,6-P2 [64, 91, 113] . These agents promote glycogen breakdown by a mechanism independent of cyclic AMP. Glycogen breakdown leads to an increase in Fru-6-P and in Fru-2,6-P2 concentration because the accumulation of hexose 6-phosphates is not counteracted, as is the case with glucagon, by an inactivation of PFK-2 and an activation of FBPase-2. Since vasopressin and a-agonists have little effect on pyruvate kinase [114] [115] [116] [117] and since they stimulate pyruvate dehydrogenase [118, 119] , the increase in lactate output is less than expected from the changes in Fru-2,6-P2. In isolated hepatocytes, the mechanism responsible for the increase in Fru-2,6-P2 is the increased supply of Fru-6-P either from glycogen, glucose or gluconeogenic precursors. The same mechanism applies in the livers of anaesthetized rats. In livers of conscious animals, however, the glucose-induced increase in Fru-2,6-P2 concentration is not accompanied by an increase in hexose 6-phosphate concentration [78, 98, 120] or a stable change in the activity of PFK-2 [78] . The mechanism involved is unknown but one cannot exclude that an increase in Fru-6-P could have been masked artifactually. Indeed, in the time interval between killing of the animal and sampling of the liver, the hexose 6-phosphate pool may become depleted as a result of stimulation of glycolysis.
In the third situation, liver glycolysis is stimulated by anoxic conditions. This emergency situation probably does not occur under physiological conditions but can be readily obtained in isolated liver preparations. Under these conditions the concentration of Fru-2,6-P2 remains low and therefore is not responsible for this burst of glycolytic activity [121] . The fall in ATP concentration and the increase in ADP and sn-glycerol 3-phosphate which are observed during anoxia may all contribute to decrease PFK-2 activity and hence Fru-2,6-P2 concentration. By contrast with liver, hypoxic or anoxic conditions can occur in muscle under physiological conditions. As for the anoxic liver, it appears that the major stimulation of glycolysis in muscle during tetanic contraction is not due to an increase in Fru-2,6-P2 concentrations [28, 102] .
Relationship between glycolytic flux and Fru-2,6-P2 concentration in extra-hepatic tissues Fru-2,6-P2 has been detected in all mammalian tissues including red blood cells. Although a previous study failed to detect Fru-2,6-P2 in erythrocytes [122] , more recent studies [122a] established that 0.02-0.3 nmol of Fru-2,6-P2/g could be detected depending on the conditions and that the previous failure could be explained by the presence of glycerate 2,3-bisphosphate, which inhibits both PFK-2 and the enzyme used to measure Fru-2,6-P2 in extracts.
To identify the conditions in which Fru-2,6-P2 could exert a control on glycolysis, the simplest approach is to search for conditions or treatments that change both glycolysis and Fru-2,6-P2 concentration in the same direction. Table 3 summarizes data taken from the literature. In general, the rate of glycolysis was regulated by substrate supply (glucose), energy demand (e.g. anoxia), or hormones (e.g. adrenaline, insulin). There was a paralleli'sm between the glucose-!dependent increase in glycolysis and in Fru-2,6-P2 in all tissues studied except Vol. 245 in cultured astrocytes [123] and sperm cells [124] . Such a parallelism did not exist when glycolysis was stimulated by anoxia. Therefore, when energy provision by glycolysis becomes a major issue for the cell, the predominant control is probably exerted by adenine nucleotides, Pi and citrate rather than by Fru-2,6-P2.
On the other hand, during aerobiosis, Fru-2,6-P2 could play a regulatory role in the glucose-sparing effect of fatty acids and ketone bodies (the so-called glucose/fatty acids cycle). Indeed, the administration of fatty acids to hepatocytes or ketone bodies to perfused hearts decreases the glycolytic rate and the concentration of Fru-2,6-P2 in parallel (L. Hue, L. Maisin & M. H. Rider, unpublished work). The latter is probably caused by an increased citrate concentration which inhibits PFK-2. Therefore, during aerobiosis, Fru-2,6-P2 could be regarded as a glycolytic signal which is turned on by glucose availability and switched off by the presence of alternative fuels.
Hormones such as insulin and adrenaline increased both glycolysis and Fru-2,6-P2 in skeletal muscle and heart [45, 102, 125, 126] . This relationship does not mean that Fru-2,6-P2 is the sole mechanism of control. More likely, the increase in Fru-2,6-P2 is part of a concerted mechanism involving the stimulation of various glycolytic steps such as glucose transport, hexokinase, PFK-1, pyruvate kinase and pyruvate dehydrogenase. The description of the specific effects of adrenaline and insulin on these steps is outside the scope of this review.
Besides these general mechanisms of control, there are some tissue-specific regulations. In brain, renal medulla, tetanic muscle, erythrocytes and sperm cells, glycolysis is the sole, or at least the major, mechanism for energy provision [2] . In red blood cells [122a] , sperm cells [124] and during tetanus in muscle [28, 102] , Fru-2,6-P2 does not seem to be involved in glycolytic control because its concentration is either too low or unrelated to changes in the glycolytic rate. For brain and kidney, the limited information available does not allow any conclusion about the role of Fru-2,6-P2 to be drawn. Interestingly, Fru-2,6-P2 concentration in brain does not decrease upon fasting [15] .
Fru-2,6-P2 is expected to be the regulator par excellence when glycolysis serves an anabolic role since it is able to relieve the inhibition of PFK-1 by ATP. As discussed above, this is probably the case for the liver where lipogenesis is-associated with glycolysis and high concentration of Fru-2,6-P2. The same causal relationship probably holds true in mammary glands where the concentration of Fru-2,6-P2 increases 3-fold during lactation [127] . For white adipose tissue, however, the situation is not clear since insulin, which is known to stimulate both glycolysis and lipogenesis, has been shown to decrease Fru-2,6-P2 concentration [128] (see however [129] and below).
In all tissues, as in the liver, control of Fru-2,6-P2 concentration depends on the relative activity of PFK-2/FBPase-2. A rise in Fru-6-P concentration favours the synthesis of Fru-2,6-P2 provided that FBPase-2 is inhibited. The latter restriction might not hold for all tissues. Indeed, the Ki of FBPase-2 for Fru-6-P is relatively high in skeletal muscle [63, 77] . This could also be the case for sperm cells and astrocytes and could explain why glucose does not increase Fru-2,6-P2 concentration.
Regulation of PFK-2/FBPase-2 activity by cyclic AMP-dependent protein kinase seems to be restricted to the liver enzyme and therefore cannot explain the stimulatory effect of adrenaline on Fru-2,6-P2 in muscle and heart. Alternatively, it is proposed that this effect of adrenaline on Fru-2,6-P2 concentration [102, 130] results from a stimulation of glycogen breakdown and an increased Fru-6-P concentration. Similarly, insulin increases Fru-6-P concentration by stimulating glucose transport. However, this increase is too small to explain the changes in Fru-2,6-P2 concentration in muscle and heart [45, 102, 125] . The changes in Fru-2,6-P2 brought about by insulin can be explained by an activation of PFK-2 (increase in Vmax., without change in Km) that has been indeed observed in heart [125] . This insulin-induced activation of PFK-2 persists after partial purification of the enzyme, consistent with the possibility of covalent modification. Phosphorylation by cyclic AMP-dependent protein kinase or protein kinase C has been excluded and the mechanism responsible for the modification has still to be elucidated. A similar phenomenon may exist in skeletal muscle but has not yet been demonstrated. It would also be interesting to know the effect of insulin on the activity of FBPase-2, particularly in skeletal muscle, where the FBPase-2 activity is 10 times that of the kinase.
There is a discrepancy in the literature concerning the hormonal regulation of Fru-2,6-P2 concentration in white adipose tissue. While adrenaline treatment was reported to decrease and insulin to increase Fru-2,6-P2 concentration in epididymal fat pads [129] , noradrenaline had little effect and insulin decreased Fru-2,6-P2 in isolated adipocytes [128] . The reasons for this discrepancy are unknown. On the other hand, it is clear that adrenaline causes stable changes in PFK-1 activity (an increased apparent affinity for Fru-6-P and a small decrease in Vmax. [131, 132] ). Since these changes could not be interpreted in terms of Fru-2,6-P2, it has been proposed that they could result from alterations in the concentration of other PFK-1 ligands, namely fatty acids [132] . Alternatively, these changes could be caused by phosphorylation of PFK-1 by cyclic AMP-dependent protein kinase. The latter has been demonstrated both in vitro and in vivo [36, 133] . The [134] . The biochemical mechanism of this phenomenon, known for 60 years, is not yet fully understood. The difference can be accounted for, at least in part, by qualitative and quantitative changes in enzyme activity and-hexose transport [135, 136] . Recent work has shown that, on top of the differences already described, the Fru-2,6-P2/PFK-2 system might play an important role in the maintenance of a high glycolytic rate in these cells. The evidence is based on the study of established lines of tumour cells and, in particular, on the study of the effect of growth factors, tumour promoters like phorbol esters, and oncogenic viruses on glycolysis in fibroblasts.
In established lines of cancer cells, the concentration of Fru-2,6-P2 is either the same (rat hepatoma HTC cells [137] , Ehrlich ascites tumour cells [138] ) or higher (HeLa cells [139] , adenocarcinoma [140] ) than in the corresponding normal tissues. In HTC cells, the properties of PFK-2 are modified in such a way that the enzyme has lost the characteristic properties of the original liver type [141] .
In quiescent fibroblasts stimulated by high mitogenic concentrations of insulin, growth factors or phorbol esters, there is a stimulation of glycolysis and a concomitant increase in Fru-2,6-P2 concentration, activation of PFK-2 and stimulation of glucose transport [92, [142] [143] [144] [145] .
A similar situation is obtained when chick embryo fibroblasts are transformed by retroviruses carrying either the v-src or v-fps, but not the v-mil and/or v-myc, oncogenes [146] . The glycolytic and Fru-2,6-P2/PFK-2 changes induced by the Rous sarcoma virus carrying the v-src oncogene depend on the tyrosine-specific protein kinase activity of pp60v-src, the oncogene product. The comparison of the effects of v-src with those of phorbol esters on Fru-2,6-P2 concentration suggests that both result from the stimulation of a step which is controlling PFK-2 activation and which is also controlled by protein kinase C. The time-course of the changes in PFK-2 activity argue against a direct activation of PFK-2 by protein kinase C or pp60v-src. The exact mechanism is not known.
The changes in the PFK-2/Fru-2,6-P2 system occurring in transformed fibroblasts are not the only determinants of the 'glycolytic phenotype', because glucose transport is also stimulated [147] . The relative contribution of these two phenomena to the overall control of glycolysis is unknown. Nevertheless, a characteristic and intriguing feature of proliferating cells is their relatively high Fru-2,6-P2 content. Similar changes in Fru-2,6-P2 concentrations have also been observed during resumption of metabolic activities in plants [148] and in spores [149] . Moreover, the highest concentrations of Fru-2,6-P2 ever recorded are found in fibroblasts treated with phorbol esters or transformed.by v-src. These concentrations (more than 50 nmol/g [146] ) are more than 10 times higher than that required for near-maximal stimulation of PFK-1. Therefore it is tempting to speculate that Fru-2,6-P2 could either influence metabolic pathways other than glycolysis or be an intermediate in some other reactions (e.g. phosphorylation or osylation). It is not known whether these huge increases in Fru-2,6-P2 concentration are required to keep the cells in a proliferative phase.
Metabolic detours from the glycolytic pathway As discussed in a previous review [22] , the similarity between Fru-2,6-P2 and some other bisphosphoesters related to the glycolytic pathway is striking. Like Fru-2,6-P2, glucose 1,6-bisphosphate and glycerate 2,3-bisphosphate are not true intermediates of glycolysis and their metabolisms involve detours from the glycolytic pathway. Neither are they direct precursors of the pathway. They are synthesized from glycolytic intermediates which are either substrates or products of the reactions they control. They all act as cosubstrates or effectors of reactions in the pathway.
The comparison can be extended to PFK-2/FBPase-2 and the glucose bisphosphatase family of enzymes [150] . These enzymes catalyse phosphoryl transfer reactions involving the formation of a phosphorylated enzyme intermediate from the bisphosphates. Similarly, the synthesis and degradation of glycerate 2,3-bisphosphate is catalysed by a multifunctional enzyme and involves the intermediate formation of a phosphorylated histidyl residue [151] . We tend to believe that this striking analogy is not fortuitous. It may indicate that metabolic detours are a general mechanism developed by the cell to synthesize effectors which control metabolic pathways. It also suggests that other enzymes could exist which use Fru-2,6-P2 as a phosphoryl donor. In this context, it is worth mentioning that the mechanism of ribose 1,5-bisphosphate synthesis is not yet elucidated and that the understanding of glucose 1 ,6-bisphosphate hydrolysis in several tissues is far from complete [150] .
Conclusion
The main role of Fru-2,6-P2 is to control PFK-1 activity and hence glycolysis. Therefore, it is a glycolytic signal. It behaves as an integrator of information from various metabolisms on a single point of control, PFK-1. Cyclic AMP has the opposite effect by extending and spreading information from one molecule to various metabolisms. The difference in behaviour stems from the remarkable properties of cyclic AMP-dependent protein kinase, which is a multisubstrate enzyme, whereas PFK-2 and FBPase-2 are multimodulated enzymes and, thus, can act as metabolic integrators. Yet another difference is the hierarchy between the two signals: Fru-2,6-P2 is indeed controlled by cyclic AMP but cannot control cyclic AMP. Therefore, Fru-2,6-P2 can be regarded as a third messenger of hormone action.
Although Fru-2,6-P2 is present in all tissues studied so far, it can not be regarded as the ubiquitous regulator of glycolysis under all conditions. It is suggested that its role is related to the metabolic significance of glycolysis which is an amphibolic pathway. Fru-2,6-P2 probably plays no role in tissues that depend exclusively on glycolysis for their energy supply. In tissues that can use alternative fuels, a fall in Fru-2,6-P2 concentration could signal the presence of non-glycolytic substrates and, by doing so, it can contribute to the glucose-sparing effect of these substrates. In skeletal muscle and heart, Fru-2,6-P2 is also involved in the control of glycolysis by adrenaline and insulin. In liver, it is a major control element for switching from glycolysis to gluconeogenesis. In this Vol. 245 tissue, it is also probably important in the control of substrate provision for lipogenesis. Finally, one can speculate that the highest concentrations. of Fru-2,6-P2 which are found in transformed cells could not only keep PFK-1 and glycolysis active but also interfere with other pathways essential for cell proliferation.
